drugset / Trial / NCT06439771
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Timeline
- Start
- 2024-04-23
- Primary completion
- 2026-07-30
- Completion
- 2028-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL202 | Unknown | — | Intravenous |